References
- Ablynx. News release: Ablynx announces positive topline results from a phase 2b study of its anti-IL-6r nanobody, vobarilizumab (alx-0061), as a monotherapy in RA. 2016 Jul 7.
- Staff. NICE approves UCB Pharma’s Cimzia. PMLiVE. 2016 Jul 12.